Status:
UNKNOWN
68Ga-FAPI PET/CT in Patients With Various Fibrotic Disease
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University
Conditions:
Fibrosis
Positron-Emission Tomography
Eligibility:
All Genders
18-85 years
Phase:
EARLY_PHASE1
Brief Summary
To evaluate the potential value of 68Ga-FAPI-04 positron emission tomography/ computed tomography (PET/CT) for the diagnosis and prognosis in fibrotic disease
Detailed Description
Subjects with fibrotic disease underwent 68Ga-FAPI-04 PET/CT scanning. Fibrosis lesion uptake was quantified by the maximum standard uptake value (SUVmax). Subjects also received the conventional clin...
Eligibility Criteria
Inclusion
- adult patients (aged 18 years or order)
- patients with suspected or new diagnosed fibrotic disease (supporting evidence may include , BBI, MRI, CT and pathology report)
- patients who had scheduled 68Ga-FAPI-04 PET/CT scan
- patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee
Exclusion
- patients with pregnancy
- the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04831034
Start Date
April 1 2021
End Date
April 1 2024
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005